Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Mesenchymal Cell News
Mesenchymal Cell News is an online resource that delivers updates on the latest research in the mesenchymal stem cell field.
OCT4-Driven PER1 Activation Promotes Odontogenic Differentiation in Senescent SCAP Spheres
[International Journal of Oral Science] Researchers demonstrated that the pluripotency regulator octamer-binding transcription factor 4 (OCT4) promoted odontogenic differentiation by activating period circadian regulator 1 (PER1) in replicative senescent stem cells from apical papilla (SCAP) spheres.
Bioprocess Design and Optimization of Extracellular Vesicles Derived from Mesenchymal Stromal Cells
[ACS Nano] Scientists established an analytical toolbox comprising scattering and fluorescence mode nanoparticle tracking analysis, fluorescence-based flow cytometry, and multidetector analytical size-exclusion chromatography.
Multifunctional Inverse Opal Nerve Guidance Conduits Loaded with Mesenchymal Stem Cells for Peripheral Nerve Repair
[ACS Applied Materials & Interfaces] Researchers presented a type of multifunctional inverse opal nerve guidance conduit integrating bone marrow MSCs for peripheral nerve repair.
Type 2 Diabetes-Induced Molecular and Functional Impairment of Adipose Tissue-Derived Mesenchymal Stromal Cells (ASCs) and Interferon Gamma Priming for Enhanced Diabetic ASC-Based Therapy
[Stem Cell Reviews and Reports] The authors investigated transcriptomic alterations and therapeutic efficacy of ASCs from type 2 diabetes (dASCs) patients in experimental diabetes, compared to healthy donors, and evaluated whether inflammatory priming could enhance dASC functionality.
YTHDF3 Enhances Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoporosis by Promoting TBX19 Expression
[Cell Proliferation] Investigators found that osteoporosis in rats correlates with severe bone loss and diminished osteogenic potential of bone marrow MSCs, accompanied by down-regulation of the m6A reader YTHDF3.
Research on GM1 Bound bMSCs Loaded with SF Hydrogel for Spinal Cord Injury Repair
[Journal of Translational Medicine] Scientists developed a silk fibroin (SF)-based hydrogel for the sustained delivery of monosialotetrahexosylganglioside (GM1) and bone marrow-derived MSCs and evaluated its therapeutic effect in a rat model of spinal cord injury.
Soluble PD-L1-Secreting Umbilical Cord-Derived Mesenchymal Stromal Cells Transiently Attenuate Established Xenogeneic T Cell Activation In Vivo
[Scientific Reports] Researchers showed that engineered MSCs secreting soluble PD-L1 can transiently suppress T cell activation in vivo, highlighting a potential strategy for controlling immune overactivation.
Mesenchymal Stromal Cell Therapy for Systemic Lupus Erythematosus: Mechanisms, Clinical Translation, and Future Directions
[Stem Cell Research & Therapy] The authors asses the potential of MSCs in reconciling the unmet need for effective systemic Lupus Erythematosus therapies by examining their immunomodulatory mechanisms, clinical efficacy, and safety.
Triphenyl Phosphate Promotes Lipid Accumulation in Human Mesenchymal Stem Cells through Metabolic Stress Pathways
[Archives of Toxicology] Scientists investigated the impact of triphenyl phosphate (TPhP) on human MSC differentiation and cell stress. TPhP exposure led to significant lipid accumulation without activation of adipogenic differentiation programs and markedly reduced mineralization.
BioRestorative Completes Phase II Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
[BioRestorative Therapies, Inc. ] BioRestorative Therapies, Inc. announced that the last patient has been dosed in its fully enrolled Phase II clinical trial evaluating BRTX-100 for the treatment of chronic lumbar disc disease, completing treatment administration in the Company’s lead clinical program.
TriCelX Files FDA IND for XytriX™ in Chronic Traumatic Encephalopathy (CTE)
[TriCelX, Inc.] TriCelX, Inc. has submitted a Phase I/II Investigational New Drug application to the US FDA for XytriX™ — its proprietary allogeneic UC-MSC biotherapeutic, ethically sourced from donated human birth tissue — for adults with confirmed or probable Chronic Traumatic Encephalopathy.
Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS)
[Neurology] In this randomized, double-blind, placebo-controlled Phase I/II trial, patients with progressive multiple sclerosis enrolled at four Norwegian tertiary hospitals received a single intrathecal injection of autologous bone marrow–derived MSCs in a crossover design.
Mesenchymal Cell News covers topics such as the isolation, identification, and culturing conditions of mesenchymal stem cells, as well as their cellular characterization, behavior and differentiation capacities. We also include research that focuses on identifying tissue sources of mesenchymal stem cells and their potential therapeutic applications in regenerative medicine and cellular therapies.
